Evidence map›Paper›PMID 30315392›Full record

ArticleJournal of cancer survivorship : research and practice2018

Physical symptoms in long-term survivors of rare cancer.

Nora K Horick, Ariela Muzikansky, Hilda L Gutierrez, Kristina L Boyd, Dianne M Finkelstein

Abstract read
In one paragraph

Article in Journal of cancer survivorship : research and practice, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 34 citations in OpenAlex.

  1. Article
  2. A scoping review of pain and tobacco use among cancer survivors.Annals of behavioral medicine : a publication of the Society of Behavioral Medicine · 2025
    Article
  3. Article
  4. Article
  5. Review
  6. Path analysis of survivorship care needs, symptom experience, and quality of life among multiethnic cancer survivors.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Nora K HorickMassachusetts General Hospital Biostatistics Center, 50 Staniford St. Suite 560, Boston, MA, 02114, USA.
Ariela MuzikanskyMassachusetts General Hospital Biostatistics Center, 50 Staniford St. Suite 560, Boston, MA, 02114, USA.
Hilda L GutierrezMassachusetts General Hospital Biostatistics Center, 50 Staniford St. Suite 560, Boston, MA, 02114, USA.
Kristina L BoydMassachusetts General Hospital Biostatistics Center, 50 Staniford St. Suite 560, Boston, MA, 02114, USA.
Dianne M FinkelsteinMassachusetts General Hospital Biostatistics Center, 50 Staniford St. Suite 560, Boston, MA, 02114, USA. dfinkelstein@mgh.harvard.edu.ORCID 0000-0001-9564-8181
Massachusetts General Hospital · USHarvard University · US

Funding

Rare Cancer Genetics RegistryR01CA160233 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI FINKELSTEIN, DIANNE M · 2012 to 2016
$2.4M
Rare Cancer Genetics RegistryRC1CA144706 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI FINKELSTEIN, DIANNE M · 2009 to 2010
$988k
Analysis of Risks and Outcomes for Rare CancersR03CA167570 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI FINKELSTEIN, DIANNE M · 2012 to 2013
$169k
NCI NIH HHS R01 CA160233NCI NIH HHS R03 CA167570NCI NIH HHS RC1 CA144706
6 · The paper itself

Abstract

purposeAdvances in cancer detection and treatment have resulted in a growing population of long-term survivors, but even years after treatment has concluded, many survivors report physical symptoms that interfere with daily living. While there are studies of late effects following common cancers, less is known about these complications in rare cancers. This study focuses on the physical symptoms reported by long-term survivors enrolled in the NIH-sponsored Rare Cancer Genetics Registry.

methodsThe Rotterdam Symptom Checklist-Modified was administered to evaluate the severity of physical symptoms commonly reported by long-term cancer survivors. Logistic regression was used to assess association between symptoms and demographic and clinical factors.

resultsIn 309 subjects with a median time of 7.6 years from a diagnosis of one or more rare cancers, the median number of symptoms present per participant was 7. The most prevalent symptom reported was tiredness/lack of energy, which was present/very bothersome in 70%/25% of registrants. Women, non-whites, current smokers, and upper GI cancer survivors are particularly affected. Overall, symptom prevalence was similar across rare cancer types, time since diagnosis, and type of treatment.

conclusionsRare cancer survivors continue to experience troublesome symptoms many years after diagnosis, regardless of cancer type or treatment modality. IMPLICATIONS FOR CANCER SURVIVORS: There is a need for continued emphasis on smoking cessation in cancer survivors as well as enhanced monitoring of long-term complications in female, non-white, and upper GI cancer survivors.

Indexed as

Cancer SurvivorsQuality of LifeRare DiseasesSymptom AssessmentAdultAgedAged, 80 and overFatigueFemaleHumansMaleMiddle AgedNeoplasmsPainPrevalenceRegistriesLong-term survivorsQuality of lifeRare cancerRotterdam symptom checklist-modified

Identifiers

PMID30315392
PMCPMC6503956
OpenAlexW2895888590

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.